This site is intended for UK healthcare professionals
Medscape UK Univadis Logo
Medscape UK Univadis Logo

Semaglutide injection

Updated 2 Feb 2023 | GLP-1 agonists


Solution for injection containing semaglutide.

Drugs List

  • OZEMPIC 0.25mg/0.19ml solution for injection 1.5ml pre-filled pen
  • OZEMPIC 0.5mg/0.37ml solution for injection 1.5ml pre-filled pen
  • OZEMPIC 1mg/0.74ml solution for injection 3ml pre-filled pen
  • semaglutide 0.25mg/0.19ml solution for injection 1.5ml pre-filled device
  • semaglutide 0.5mg/0.37ml solution for injection 1.5ml pre-filled device
  • semaglutide 1mg/0.74ml solution for injection 3ml pre-filled device
  • Therapeutic Indications


    Type 2 diabetes (NIDDM) not controlled by diet,weight loss & exercise alone

    The treatment of adults with insufficiently controlled type 2 diabetes as an adjunct to diet and exercise.

    As monotherapy
    In patients where metformin is consider inappropriate due to contraindication or intolerance.

    Adjunctive therapy
    In addition to other treatments for diabetes.



    Initial dose
    0.25mg once a week for 4 weeks.

    0.5mg once a week. The dose can be increased to 1mg once a week after at least 4 weeks with a dose of 0.5mg once a week.

    Dose greater than 1mg weekly is not recommended.

    Additional Dosage Information

    When semaglutide is added to existing sulfonylurea or insulin therapy, a reduction in the dose of sulfonylurea or insulin should be considered to reduce the risk of hypoglycaemia.

    Missed dose
    If a dose is missed within 5 days of scheduled administration, it should be administered as soon as possible.
    If a dose is missed by more than 5 days, the missed dose should be skipped and the next should be administered on scheduled day.
    In each case, the regular once weekly dosing schedule should be resumed.


    For subcutaneous injection only.

    To be administered once a week at any time of the day, can be given with or without meals.

    If necessary, the day of the weekly administration can be changed as long as the interval between 2 doses is at least 72 hours. After selecting a new dosing day, the once a week dosing schedule should be continued.


    Children under 18 years
    End stage renal disease
    New York Heart Association class IV failure

    Precautions and Warnings

    Females of childbearing potential
    Patients over 75 years
    Diabetic retinopathy
    History of pancreatitis
    Severe hepatic impairment
    Severe renal impairment

    For single patient use only
    For subcutaneous use only
    Use only if the solution is clear and colourless
    Insulin dose adjustment: Reduce insulin dose gradually and monitor for DKA
    Monitor patient for hypoglycaemia if adjunct to insulin or sulfonylurea
    Advise patient to seek medical advice if symptoms of dehydration occur
    Advise patients to report symptoms of acute pancreatitis immediately
    Discontinue if pancreatitis is suspected
    Do not restart treatment following confirmation of pancreatitis
    May affect the gastro-intestinal absorption of other drugs
    Discontinue treatment at least 2 months before a planned pregnancy
    Female: Ensure adequate contraception during treatment
    Advise patient on fluid replacement if GI side effects occur
    Patient to inform DVLA if fitness to drive impaired or hypoglycaemic risk

    Caution and close monitoring should be used in diabetic retinopathy patients treated with semaglutide and insulin, as an increased risk of developing diabetic retinopathy complications has been observed in such patients.

    Gastrointestinal adverse reactions associated with semaglutide should be considered when treating patients with impaired renal function, due to risk of dehydration and deterioration of renal function.

    Pregnancy and Lactation


    Semaglutide is contraindication during pregnancy.

    The manufacturer recommends that semaglutide should not be used during pregnancy and semaglutide should be discontinued at least 2 months before a planned pregnancy due to semaglutide's long half-life.

    Animal studies have shown reproductive toxicity. Human data is limited and as such a potential risk cannot be ruled out.


    Semaglutide is contraindicated during breastfeeding.

    The manufacturer does not recommend breastfeeding whilst taking semaglutide.

    Animal studies have shown semaglutide to be excreted in breast milk, however presence in human breast milk is unknown. Effects on exposed infants are unknown.

    Side Effects

    Abdominal distension
    Abdominal pain
    Acute pancreatitis
    Anaphylactic reaction
    Decreased appetite
    Diabetic ketoacidosis
    Diabetic retinopathy complications
    Elevated amylase levels
    Elevated serum lipase
    Gastroesophageal reflux disease
    Increased heart rate
    Injection site reactions
    Retinal photocoagulation
    Vitreous haemorrhage
    Weight loss


    It is strongly recommended that the UK National Poisons Information Service be consulted on cases of suspected or actual overdose where there is doubt over the degree of risk or about appropriate management.

    The following number will direct the caller to the relevant local centre (0844) 892 0111

    Information may be obtained if you have access to ToxBase the primary clinical toxicology database of the National Poisons Information Service. This is available via password on the internet ( ) or if this is unavailable at the backup site ( ).

    Further Information

    Last Full Review Date: June 2020

    Reference Sources

    Summary of Product Characteristics: Ozempic 0.25mg, 0.5mg, 1mg solution for injection in pre-filled pen. Novo Nordisk Limited. Revised March 2021.

    MHRA Drug Safety Update June 2019
    Available at:
    Last accessed: 28 August 2019

    NICE Evidence Services Available at: Last accessed: 10 February 2020

    US National Library of Medicine. Toxicology Data Network. Drugs and Lactation Database (LactMed).
    Available at:
    Semaglutide Last revised: 03 December 2018
    Last accessed: 14 January 2019

    Access the full UK drug database with a FREE Medscape UK Account
    It takes just a few minutes, and you’ll get unlimited access to information on over 11,000 UK drugs.
    Register for Free

    Already a member? Log in

    Medscape UK | Univadis prescription drug monographs & interactions are based on FDB Multilex Content

    FDB Logo

    FDB Disclaimer : FDB Multilex is intended for the use of healthcare professionals and is provided on the basis that the healthcare professionals will retain FULL and SOLE responsibility for deciding what treatment to prescribe or dispense for any particular patient or circumstance.